Axicabtagene ciloleucel

Therapeutic indications

Axicabtagene ciloleucel is indicated for:

Primary mediastinal large B-cell lymphoma (PMBCL)

Population group: only adults (18 years old or older)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 × 10⁶ CAR-positive viable T cells per kg of body weight once

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Population group: only adults (18 years old or older)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 × 10⁶ CAR-positive viable T cells per kg of body weight once

Diffuse large B-cell lymphoma (DLBCL)

Population group: only adults (18 years old or older)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 × 10⁶ CAR-positive viable T cells per kg of body weight once

High-grade B-cell lymphoma (HGBL)

Population group: only adults (18 years old or older)

Axicabtagene ciloleucel is indicated for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 × 10⁶ CAR-positive viable T cells per kg of body weight once

Relapsed or refractory follicular lymphoma

Population group: only adults (18 years old or older)

Axicabtagene ciloleucel is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 × 10⁶ CAR-positive viable T cells per kg of body weight once

Contraindications

Axicabtagene ciloleucel is contraindicated in the following cases:

Lactation

Lactation

Effects on ability to drive and use machines

Effects on ability to drive and use machines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈